Thursday 27 Feb
Ibnsina pharma's 2024 consolidated financial statements show a 188% year-on-year surge in net profit, reaching 614.56 million Egyptian pounds, up from 213.27 million pounds in 2023 (including minority rights).
The company's sales increased during the past year to 55.84 billion Egyptian pounds, compared to 33.94 billion Egyptian pounds in 2023.
Standalone business profits also rose to 620.52 million
pounds from 246.98 million pounds. For the first nine months of 2024, net
profits were 406.51 million pounds (including minority rights), a significant
increase from 173.64 million pounds in the same period of 2023.
Sales for this nine-month period reached 38.4 billion pounds, compared to 23.8 billion pounds in 2023.
